Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

24.86 +1.21 (+5.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Amid Rapidly Rising Bird Flu Cases, Moderna Lands $176M Worth US Government Contract For Vaccine
The funds will be utilized to finalize the late-stage development and testing of a pre-pandemic mRNA-based vaccine against H5N1 avian influenza. 
Via Benzinga
Moderna Receives Project Award through BARDA's Rapid Response Partnership Vehicle Consortium to Accelerate Development of mRNA-based Pandemic Influenza Vaccine
Via ACCESSWIRE
Surprise! 3 Stocks That Are Outperforming Nvidia in 2024.
There are more marketplace opportunities than just AI which is why these stocks that are outperforming Nvidia have done so well. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Moderna And Walgreens Boots Alliance Were Among The 10 Biggest Large Cap Losers Last Week (June 23 - June 29): Are These In Your Portfolio?
10 worst performing large-cap stocks last week: Walgreens, Floor & Decor, Moderna, Birkenstock, BeiGene, Pool Corp, JD.com, Ecopetrol, International Paper, Micron. 
Via Benzinga
What's Going On With Moderna Stock Friday?
Moderna's RSV vaccine, mRNA-1345, is designed to protect adults aged 60 and older from respiratory disease caused by the RSV infection. 
Via Benzinga
In-Depth Examination Of 10 Analyst Recommendations For Moderna
Via Benzinga
Moderna's Options: A Look at What the Big Money is Thinking
Via Benzinga
Treasure Hunt: 3 Biotech Stocks Wall Street Hasn’t Discovered Yet
Undiscovered biotech stocks can be risky but rewarding, especially when it involves mid-cap stocks with promise and no profit. 
Via InvestorPlace
EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)
Via ACCESSWIRE
Silver Prices Fell To A 6-Week Low
Silver prices held below $29 an ounce, near a six-week low, and were pressured by a strong dollar and Treasury bond yields after hawkish remarks from a Federal Reserve official. 
Via Talk Markets
Topics Bonds Economy
Exposures Debt Markets Interest Rates
CDC Advisor Panel Recommends RSV Shots In US For People Above 75 Years, Analyst Says Decision Negative For GSK
The CDC's ACIP recommends RSV vaccines for adults 75+, and for those 60-74 with chronic conditions. GSK's Arexvy is approved for adults 50-59 at risk. A decision on adults 50-59 is pending further... 
Via Benzinga
2 Stocks Down More Than 30% to Buy Right Now
These stocks have suffered as the demand for their biggest product -- the coronavirus vaccine -- waned. 
Via The Motley Fool
Exposures COVID-19
$100 Invested In This Stock 5 Years Ago Would Be Worth $900 Today
Via Benzinga
Market Whales and Their Recent Bets on MRNA Options
Via Benzinga
Smart Money Is Betting Big In MRNA Options
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Dow Nearly 100 Points Lower Amid Slumping Home Sales
Via Talk Markets
Topics Stocks
Exposures US Equities
Why Is Moderna Stock Trading Lower On Wednesday?
The CDC's Advisory Committee on Immunization Practices is set to discuss recommendations for RSV, influenza, and COVID-19 vaccines. Moderna's data shows vaccine efficacy drops to 50% after 18 months in... 
Via Benzinga
Exposures COVID-19
Moderna Crumbles After RSV Vaccine Effectiveness Pales Vs. Pfizer, GSK Shots
After 18 months, Moderna's RSV vaccine proved about 50% effective against lower respiratory tract disease. 
Via Investor's Business Daily
Beating Cancer Is Still An Everything-But-Easy Challenge That Pharmaceutical Companies Cannot Solve Overnight
On Tuesday, Merck Group revealed an unexpected decision to end a Phase III trial of its cancer drug Xevinapant. This move threatens to undermine confidence the research abilities of the Darmstadt,... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
What's Going On With Eli Lilly Stock On Tuesday?
Eli Lilly collaborates with Microsoft-backed OpenAI to leverage generative AI for developing novel antimicrobials targeting drug-resistant pathogens. This partnership supports Lilly's commitment to... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
S&P 500, Nasdaq Lurking Below Record Highs
Stocks are scattered this afternoon, as investors digest a weaker-than-expected retail sales reading from May. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a... 
Via Benzinga
Exposures COVID-19
The RBA Kept Interest Rates On Hold And Remained Hawkish
The Reserve Bank of Australia kept the cash rate at 4.35% at its June meeting, leaving borrowing costs unchanged for the fifth time. 
Via Talk Markets
OpenAI And Color Health Develop AI-Driven Cancer Care Solutions: Report
OpenAI and startup Color Health have developed an AI assistant, named 'copilot', to support physicians in creating personalized cancer care plans, emphasizing the tool's role in augmenting rather than... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
Biotechnology firm Moderna Inc. (NASDAQ: MRNA) made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA 
Via MarketBeat
Exposures COVID-19
Moderna Just Gave Investors Another Reason to Buy the Stock
The company's post-pandemic prospects are getting brighter. 
Via The Motley Fool
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine
Via ACCESSWIRE
7 Struggling Stocks to Sell Before July 2024
The stock market is riding high for now. But even a roaring bull market can't save these seven stocks to sell. 
Via InvestorPlace
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback